Central Precocious Puberty (CPP)

Precocious puberty is defined as the onset of developmental signs of sexual maturation earlier than would be expected based on population norms. This is typically delineated as puberty onset before 8 years in girls and 9 years in boys. In its most common form, central precocious puberty (CPP), sexual maturation proceeds from a premature activation of the hypothalamic–pituitary– gonadal (HPG) axis.3. The HPG axis is active during infancy, dormant during childhood, and reactivated at the onset of puberty.  

The epidemiology of CPP is somewhat nebulous, with a commonly cited prevalence range of 1 in 5000 to 1 in 10 000 children7. CPP is known to occur more frequently in girls than in boys and has different predominant causes for each sex. Idiopathic CPP, without an identifiable predisposing condition, accounts for the majority of cases of precocious puberty in girls, but is less frequent in boys 4,6,8 . Central nervous system findings such as tumors and congenital malformations are more frequently observed in boys who present with central precocious puberty 5,6,7. It is estimated that two thirds of precocious puberty cases in boys are due to neurological abnormalities5. The likelihood of an organic cause for CPP is greater in patients who present at younger ages 6,7.

References

  1. A Pediatrician's Guide to Central Precocious Puberty, Gad B. Kletter, Karen O. Klein and Yolanda Y. Wong CLIN PEDIATR published online 14 July 2014. Accessed October 22nd 2014
  2. Mayo Clinic: http://www.mayoclinic.org/diseases-conditions/precocious-puberty/basics/causes/con-20029745
  3. Saenger P. Definition, etiology and evaluation of precocious puberty. http://www.uptodate.com/contents/definition-etiology-and-evaluation-of-precocious-puberty? Accessed October 22nd 2014.
  4. Mogensen SS, Aksglaede L, Mouritsen A, et al. Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J Clin Endocrinol Metab. 2011;96:1393-1401.  Accessed October 22nd 2014
  5. Brito  VN,  Latronico  AC,  Arnhold  IJ,  Mendonça  BB. Update on the etiology, diagnosis and therapeutic man- agement of sexual precocity. Arq Bras Endocrinol Metab. 2008;52:18-31.  Accessed October 22nd 2014
  6. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358:2366-2377.  Accessed October 22nd 2014
  7. Partsch  CJ,  Sippell  WG.  Treatment  of  central  preco- cious puberty. Best Pract Res Clin Endocrinol Metab.2002;16:165-189.  Accessed October 22nd 2014
  8. Jakubowska A, Grajewska-Ferens M, Brzewski M, Sopyło B. Usefulness of imaging techniques in the diagnostics of precocious puberty in boys. Pol J Radiol. 2011;76:21-27.  Accessed October 22nd 2014

Additional Resources

The following groups are dedicated to the education and assistance of patients that suffer from CPP. Find out more about CPP by visiting these websites:

 

About Endo

Close

Endo International plc is a global specialty healthcare company focused on improving patients' lives while creating value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices through its operating companies: AMS, Endo Pharmaceuticals, Paladin Labs and Qualitest.  

Endo has global headquarters in Dublin, Ireland and US headquarters in Malvern, PA. 

Visit Endo.com

Other Companies

AMS

Paladin Labs

Qualitest